{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Trusha Adeshara",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "PUBCHEM": "^\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/3c93a65dc48e6786fe29ae55aa36cf9a902fe8c6/export/conso-names.belns",
      "DOID": "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns",
      "HP": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
    },
    "path": "receptors/forest2019.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Moreover, neurodegeneration correlates best with neurofibrillary tangle burden [3]",
      "key": "5c687e6b05006829be43000835394f63",
      "line": 78,
      "relation": "association",
      "source": 57,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Moreover, neurodegeneration correlates best with neurofibrillary tangle burden [3]",
      "key": "5b07aaecdfaee96d74a4e0ec913a448f",
      "line": 78,
      "relation": "association",
      "source": 52,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Abeta is produced via sequential proteolytic cleavage of the amyloid precursor protein (APP) by the processing enzymes, gamma-secretase and beta-secretase (BACE) [14]",
      "key": "ba81f59f7ef78601d123e00a0b7bb44f",
      "line": 83,
      "relation": "increases",
      "source": 31,
      "target": 35
    },
    {
      "key": "efd5ba30e265a309b2712bb6247763cd",
      "relation": "partOf",
      "source": 22,
      "target": 31
    },
    {
      "key": "6e02d493da709ba62bde9f5385d804e4",
      "relation": "partOf",
      "source": 34,
      "target": 31
    },
    {
      "key": "5efa9ea30f0b6cb4a55908d43e25d2ea",
      "relation": "hasVariant",
      "source": 34,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Additional neuroprotective strategies relevant to AD include regulating APP [43], neurotransmitter receptors (e.g., [44]), downregulating stress kinase signaling cascades [45–47], blocking activation of caspases (e.g., [48]), and/or upregulating cell survival pathways [49–52].",
      "key": "f4ed9eb54982e1ed940a9835581004b2",
      "line": 90,
      "relation": "regulates",
      "source": 34,
      "target": 21
    },
    {
      "key": "b0dfc23fa1e426b2341cea00110d7843",
      "relation": "partOf",
      "source": 36,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Abeta is produced via sequential proteolytic cleavage of the amyloid precursor protein (APP) by the processing enzymes, gamma-secretase and beta-secretase (BACE) [14]",
      "key": "f58441695e14f7e8b98de999d5fc7d83",
      "line": 84,
      "relation": "increases",
      "source": 35,
      "target": 0
    },
    {
      "key": "78d01f5659d9fcf20c63ce1881e96f4a",
      "relation": "partOf",
      "source": 0,
      "target": 26
    },
    {
      "key": "0baa2c2a8348c899cdcd96d590848667",
      "relation": "partOf",
      "source": 0,
      "target": 30
    },
    {
      "key": "a93453a39fb0a4be5411ceb62d301bd0",
      "relation": "partOf",
      "source": 0,
      "target": 29
    },
    {
      "key": "ecae19f98d1d8a9feed56e5eb38989ae",
      "relation": "partOf",
      "source": 0,
      "target": 28
    },
    {
      "key": "307b7d7a119834f010586d9e07028376",
      "relation": "partOf",
      "source": 0,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Amylin receptors were found to be regulated by Aβ [62,64] and both peptides acting via amylin receptors trigger apoptotic neuronal death [75].",
      "key": "0fd08ab0965351cc2b81b7a8cf281285",
      "line": 145,
      "relation": "regulates",
      "source": 0,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "An example of an intriguing crossover to AD for an orally active free radical scavenger,edaravone, originally developed for acute ischemic stroke, was discovered wherein strong reductions in Aβ-induced oxidation, APP processing, Aβ deposition, neuroinflammation, neurite and dendritic loss, and synaptic and behavioral dysfunction were observed in in vitro and in vivo APP models [83].",
      "key": "acfe30da41e329d117282a3790927154",
      "line": 188,
      "relation": "increases",
      "source": 0,
      "subject": {
        "modifier": "Activity"
      },
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Additional neuroprotective strategies relevant to AD include regulating APP [43], neurotransmitter receptors (e.g., [44]), downregulating stress kinase signaling cascades [45–47], blocking activation of caspases (e.g., [48]), and/or upregulating cell survival pathways [49–52].",
      "key": "6354b5ae7f5ed8f01e07ee9cbbff4859",
      "line": 91,
      "relation": "association",
      "source": 21,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Additional neuroprotective strategies relevant to AD include regulating APP [43], neurotransmitter receptors (e.g., [44]), downregulating stress kinase signaling cascades [45–47], blocking activation of caspases (e.g., [48]), and/or upregulating cell survival pathways [49–52].",
      "key": "871f33f42d3f66a974968815b66deecb",
      "line": 92,
      "relation": "negativeCorrelation",
      "source": 21,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Additional neuroprotective strategies relevant to AD include regulating APP [43], neurotransmitter receptors (e.g., [44]), downregulating stress kinase signaling cascades [45–47], blocking activation of caspases (e.g., [48]), and/or upregulating cell survival pathways [49–52].",
      "key": "7c40631b68067c6a6bf4898269be0de3",
      "line": 93,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 21,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Additional neuroprotective strategies relevant to AD include regulating APP [43], neurotransmitter receptors (e.g., [44]), downregulating stress kinase signaling cascades [45–47], blocking activation of caspases (e.g., [48]), and/or upregulating cell survival pathways [49–52].",
      "key": "a3f0ff06499afb6a909019ccf01296ef",
      "line": 94,
      "relation": "positiveCorrelation",
      "source": 21,
      "target": 19
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "It has been shown that CREB is important in neurotrophin-mediated signaling linked to neuronal survival [79] and in neuroprotection via the PI3-kinase/Akt pathway [80].",
      "key": "6cda411ed43ced0bea656de049946312",
      "line": 170,
      "relation": "association",
      "source": 21,
      "target": 9
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "It has been shown that CREB is important in neurotrophin-mediated signaling linked to neuronal survival [79] and in neuroprotection via the PI3-kinase/Akt pathway [80].",
      "key": "c8037d75fc4d2fb60900678541482f62",
      "line": 171,
      "relation": "association",
      "source": 21,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Additional neuroprotective strategies relevant to AD include regulating APP [43], neurotransmitter receptors (e.g., [44]), downregulating stress kinase signaling cascades [45–47], blocking activation of caspases (e.g., [48]), and/or upregulating cell survival pathways [49–52].",
      "key": "0213e8e5083fda04a7fb313175ed134a",
      "line": 91,
      "relation": "association",
      "source": 23,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Additional neuroprotective strategies relevant to AD include regulating APP [43], neurotransmitter receptors (e.g., [44]), downregulating stress kinase signaling cascades [45–47], blocking activation of caspases (e.g., [48]), and/or upregulating cell survival pathways [49–52].",
      "key": "6d380454c818b92b4dc45916011836cb",
      "line": 92,
      "relation": "negativeCorrelation",
      "source": 16,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Additional neuroprotective strategies relevant to AD include regulating APP [43], neurotransmitter receptors (e.g., [44]), downregulating stress kinase signaling cascades [45–47], blocking activation of caspases (e.g., [48]), and/or upregulating cell survival pathways [49–52].",
      "key": "def5a5b0920d9ad464419177a9e0a0e3",
      "line": 93,
      "relation": "negativeCorrelation",
      "source": 54,
      "subject": {
        "modifier": "Activity"
      },
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Additional neuroprotective strategies relevant to AD include regulating APP [43], neurotransmitter receptors (e.g., [44]), downregulating stress kinase signaling cascades [45–47], blocking activation of caspases (e.g., [48]), and/or upregulating cell survival pathways [49–52].",
      "key": "2a5122c6bc5983c273c911eedd3e75b3",
      "line": 94,
      "relation": "positiveCorrelation",
      "source": 19,
      "target": 21
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "It has been shown that CREB is important in neurotrophin-mediated signaling linked to neuronal survival [79] and in neuroprotection via the PI3-kinase/Akt pathway [80].",
      "key": "ac53bf1cf034940fe4fe219970366ec5",
      "line": 167,
      "relation": "association",
      "source": 19,
      "target": 15
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "It has been shown that CREB is important in neurotrophin-mediated signaling linked to neuronal survival [79] and in neuroprotection via the PI3-kinase/Akt pathway [80].",
      "key": "64671cfb0d43cb64a93ea13df1a25635",
      "line": 168,
      "relation": "association",
      "source": 19,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Behavioral deficits in AD extend to impaired attention, orientation (space and time), working memory, executive function and judgment, language function, mood (depression, anxiety, agitation), and sleep [56].",
      "key": "9e8b0ebfbcbbfa7a49b96b0681bd724a",
      "line": 100,
      "relation": "decreases",
      "source": 59,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Behavioral deficits in AD extend to impaired attention, orientation (space and time), working memory, executive function and judgment, language function, mood (depression, anxiety, agitation), and sleep [56].",
      "key": "5d8f5cf9ffaf30ea6fa5ab1788cb24a5",
      "line": 101,
      "relation": "decreases",
      "source": 59,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Behavioral deficits in AD extend to impaired attention, orientation (space and time), working memory, executive function and judgment, language function, mood (depression, anxiety, agitation), and sleep [56].",
      "key": "9beaf63704c4e18a9a3727c1a4ff2054",
      "line": 102,
      "relation": "decreases",
      "source": 59,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Behavioral deficits in AD extend to impaired attention, orientation (space and time), working memory, executive function and judgment, language function, mood (depression, anxiety, agitation), and sleep [56].",
      "key": "4ffac6c68edac9f92007bbf5a8ebb77d",
      "line": 103,
      "relation": "decreases",
      "source": 59,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Behavioral deficits in AD extend to impaired attention, orientation (space and time), working memory, executive function and judgment, language function, mood (depression, anxiety, agitation), and sleep [56].",
      "key": "5d135bdc07507fdd76b986b88b7faea4",
      "line": 104,
      "relation": "decreases",
      "source": 59,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Behavioral deficits in AD extend to impaired attention, orientation (space and time), working memory, executive function and judgment, language function, mood (depression, anxiety, agitation), and sleep [56].",
      "key": "fa315cd3cf71c42b7dc05a8438fb4ac3",
      "line": 105,
      "relation": "increases",
      "source": 59,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Behavioral deficits in AD extend to impaired attention, orientation (space and time), working memory, executive function and judgment, language function, mood (depression, anxiety, agitation), and sleep [56].",
      "key": "40f8229d3917cfc78d103cb0e4986e3e",
      "line": 106,
      "relation": "increases",
      "source": 59,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Behavioral deficits in AD extend to impaired attention, orientation (space and time), working memory, executive function and judgment, language function, mood (depression, anxiety, agitation), and sleep [56].",
      "key": "54abb34a7fb9e60d0513fc071bf05d95",
      "line": 107,
      "relation": "increases",
      "source": 59,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Behavioral deficits in AD extend to impaired attention, orientation (space and time), working memory, executive function and judgment, language function, mood (depression, anxiety, agitation), and sleep [56].",
      "key": "2237983a95c5f7693ee4cd244785ce94",
      "line": 108,
      "relation": "increases",
      "source": 59,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Behavioral deficits in AD extend to impaired attention, orientation (space and time), working memory, executive function and judgment, language function, mood (depression, anxiety, agitation), and sleep [56].",
      "key": "80cd7ecae06b6a8f24356cbd8ce2db76",
      "line": 109,
      "relation": "increases",
      "source": 59,
      "target": 62
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "In AD models, the cAMP response element-binding protein (CREB), a constitutively expressed nuclear transcription factor that regulates neuronal survival and function, has been shown to be downregulated in hippocampal neurons [50–52].",
      "key": "dc9559d2f8f7d7e0c53aaec68392cf0a",
      "line": 158,
      "relation": "decreases",
      "source": 59,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "976681bd79820445a79aa88ebb0fa9a5",
      "line": 114,
      "relation": "decreases",
      "source": 26,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "c041643f22129c87cc4c371dc72a5cce",
      "line": 115,
      "relation": "decreases",
      "source": 26,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "fffbd8b75e1de09b9b77953046af86d2",
      "line": 116,
      "relation": "increases",
      "source": 26,
      "target": 13
    },
    {
      "key": "dfc82efc544d264b1a784e9737b85ea5",
      "relation": "partOf",
      "source": 39,
      "target": 26
    },
    {
      "key": "c77e161ab274588eac5958af39a0aaaa",
      "relation": "partOf",
      "source": 42,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "0eb9c07ddf464945478df8ab9cd73e78",
      "line": 117,
      "relation": "decreases",
      "source": 30,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "11bf3c8c1e1a485621426572e4acfe70",
      "line": 118,
      "relation": "decreases",
      "source": 30,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "79ab930c15e350ed22d8254c1d6619ee",
      "line": 119,
      "relation": "increases",
      "source": 30,
      "target": 13
    },
    {
      "key": "29490712b27290671c3d513927b3c656",
      "relation": "partOf",
      "source": 53,
      "target": 30
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Amylin was originally described as a pancreatic peptide linked to diabetes via its glycemic regulation and pancreatic β-cell dysregulation [73]; however,receptors in the brain for amylin were later discovered [74], largely linked to autonomic regulation.",
      "key": "875695f286fa3745fb8e667e6e10b59e",
      "line": 139,
      "relation": "regulates",
      "source": 53,
      "target": 5
    },
    {
      "key": "4fd5ae41a076e122339ea430d7bfa882",
      "relation": "partOf",
      "source": 53,
      "target": 25
    },
    {
      "key": "834ef7e3d0950d50521cec091fc9e76a",
      "relation": "partOf",
      "source": 53,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "60edc4fba92aeb3a324c91f8a24ea819",
      "line": 120,
      "relation": "decreases",
      "source": 29,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "725eb9c3e75f5ae96823764746ea5e97",
      "line": 121,
      "relation": "decreases",
      "source": 29,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "35f9a3019e58c7ac93e63fcea64a61f2",
      "line": 122,
      "relation": "increases",
      "source": 29,
      "target": 13
    },
    {
      "key": "81926e2a8a8f3ab73586c39acb18d27b",
      "relation": "partOf",
      "source": 45,
      "target": 29
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "fd17a1ef5c1d20e48b48c48ed128013b",
      "line": 123,
      "relation": "decreases",
      "source": 28,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "49fca72044dc903c503e25b2f1b8b035",
      "line": 124,
      "relation": "decreases",
      "source": 28,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "2fb82cf3836538d79ab13c6ef4d052bf",
      "line": 125,
      "relation": "increases",
      "source": 28,
      "target": 13
    },
    {
      "key": "791603626c60425c971f448a130f1824",
      "relation": "partOf",
      "source": 44,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "b01c28208d2dac1f60efe9fa0b1cb583",
      "line": 126,
      "relation": "decreases",
      "source": 27,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "dff01a931b6efc671bb7af58d8b6e3ec",
      "line": 127,
      "relation": "decreases",
      "source": 27,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ has been shown to interact with various receptors to induce synaptic and neuronal dysfunction and death. Targets notably include cellular prion protein (PrPc) [59,60] coupled to the metabotropic glutamate receptor 5 (mGluR5) [59,61], amylin receptors [62–64], NMDA-type glutamate receptors (and perhaps AMPA glutamate receptors) [65,66], and nicotinic acetylcholine receptors (nAChRs) [67–69].",
      "key": "2da5f914a129d2a6df13cf2530d9c0f8",
      "line": 128,
      "relation": "increases",
      "source": 27,
      "target": 13
    },
    {
      "key": "683ed2b6af46d47c9de1c329b72e3d7f",
      "relation": "partOf",
      "source": 43,
      "target": 27
    },
    {
      "annotations": {
        "Anatomy": {
          "pancreas": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Amylin was originally described as a pancreatic peptide linked to diabetes via its glycemic regulation and pancreatic β-cell dysregulation [73]; however,receptors in the brain for amylin were later discovered [74], largely linked to autonomic regulation.",
      "key": "3c4f9be411929d017cd56b4b653ed569",
      "line": 134,
      "relation": "regulates",
      "source": 40,
      "target": 1
    },
    {
      "annotations": {
        "Anatomy": {
          "pancreas": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Amylin was originally described as a pancreatic peptide linked to diabetes via its glycemic regulation and pancreatic β-cell dysregulation [73]; however,receptors in the brain for amylin were later discovered [74], largely linked to autonomic regulation.",
      "key": "e04c13a395b5ce584378bb0b380a8b55",
      "line": 135,
      "relation": "association",
      "source": 40,
      "target": 60
    },
    {
      "annotations": {
        "Anatomy": {
          "pancreas": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Amylin was originally described as a pancreatic peptide linked to diabetes via its glycemic regulation and pancreatic β-cell dysregulation [73]; however,receptors in the brain for amylin were later discovered [74], largely linked to autonomic regulation.",
      "key": "dd100666ee6da239d50959f6a88ff934",
      "line": 136,
      "relation": "regulates",
      "source": 40,
      "target": 11
    },
    {
      "key": "9c1639eaade16a9133c822bddeea92ce",
      "relation": "partOf",
      "source": 40,
      "target": 25
    },
    {
      "annotations": {
        "Anatomy": {
          "pancreas": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Amylin was originally described as a pancreatic peptide linked to diabetes via its glycemic regulation and pancreatic β-cell dysregulation [73]; however,receptors in the brain for amylin were later discovered [74], largely linked to autonomic regulation.",
      "key": "0733449213d5c0026774ff55def3a42c",
      "line": 135,
      "relation": "association",
      "source": 60,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Amylin receptors were found to be regulated by Aβ [62,64] and both peptides acting via amylin receptors trigger apoptotic neuronal death [75].",
      "key": "972c5733f75b506c9ba5a040142818df",
      "line": 146,
      "relation": "increases",
      "source": 25,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Amylin receptors were found to be regulated by Aβ [62,64] and both peptides acting via amylin receptors trigger apoptotic neuronal death [75].",
      "key": "65adf7b3b36f6489460c3ad85a3588c0",
      "line": 147,
      "relation": "increases",
      "source": 24,
      "target": 12
    },
    {
      "key": "19761b0141e544093d18c2efa76d14fc",
      "relation": "partOf",
      "source": 33,
      "target": 24
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "In AD models, the cAMP response element-binding protein (CREB), a constitutively expressed nuclear transcription factor that regulates neuronal survival and function, has been shown to be downregulated in hippocampal neurons [50–52].",
      "key": "3e96150df399f137370d9187d7301478",
      "line": 154,
      "relation": "regulates",
      "source": 38,
      "target": 19
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "It has been shown that CREB is important in neurotrophin-mediated signaling linked to neuronal survival [79] and in neuroprotection via the PI3-kinase/Akt pathway [80].",
      "key": "142dd17f61f72244a950cbaa2b8ef209",
      "line": 168,
      "relation": "association",
      "source": 38,
      "target": 19
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "In AD models, the cAMP response element-binding protein (CREB), a constitutively expressed nuclear transcription factor that regulates neuronal survival and function, has been shown to be downregulated in hippocampal neurons [50–52].",
      "key": "16f2d04e2e5c05fca2f3f33848855ea0",
      "line": 155,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 38,
      "target": 8
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "It has been shown that CREB is important in neurotrophin-mediated signaling linked to neuronal survival [79] and in neuroprotection via the PI3-kinase/Akt pathway [80].",
      "key": "7991cfb325166a251518655abf6095d6",
      "line": 166,
      "relation": "association",
      "source": 38,
      "target": 15
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "It has been shown that CREB is important in neurotrophin-mediated signaling linked to neuronal survival [79] and in neuroprotection via the PI3-kinase/Akt pathway [80].",
      "key": "72c9389764e85b586d703a926b6099c1",
      "line": 169,
      "relation": "association",
      "source": 38,
      "target": 9
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "It has been shown that CREB is important in neurotrophin-mediated signaling linked to neuronal survival [79] and in neuroprotection via the PI3-kinase/Akt pathway [80].",
      "key": "09c392ad6c2cdc433ad0fecdbb0a9054",
      "line": 171,
      "relation": "association",
      "source": 38,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Contributing to a feedforward mechanism, CREB is believed to upregulate neurotrophin expression and activity, importantly, brain derived neurotrophic factor (BDNF), which is important in modulating synaptic plasticity [81], and a neurotrophin target receptor, the tropomyosin receptor kinase receptor B (TrkB) [82]",
      "key": "8c6a02374a836b9e7c39a68af50824f9",
      "line": 177,
      "relation": "directlyIncreases",
      "source": 38,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Contributing to a feedforward mechanism, CREB is believed to upregulate neurotrophin expression and activity, importantly, brain derived neurotrophic factor (BDNF), which is important in modulating synaptic plasticity [81], and a neurotrophin target receptor, the tropomyosin receptor kinase receptor B (TrkB) [82]",
      "key": "f49b513045057d21ef1be552462f9bb2",
      "line": 178,
      "object": {
        "modifier": "Activity"
      },
      "relation": "directlyIncreases",
      "source": 38,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Contributing to a feedforward mechanism, CREB is believed to upregulate neurotrophin expression and activity, importantly, brain derived neurotrophic factor (BDNF), which is important in modulating synaptic plasticity [81], and a neurotrophin target receptor, the tropomyosin receptor kinase receptor B (TrkB) [82]",
      "key": "e44e7e37dde05acdb1f1da264fa59875",
      "line": 179,
      "relation": "directlyIncreases",
      "source": 38,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Contributing to a feedforward mechanism, CREB is believed to upregulate neurotrophin expression and activity, importantly, brain derived neurotrophic factor (BDNF), which is important in modulating synaptic plasticity [81], and a neurotrophin target receptor, the tropomyosin receptor kinase receptor B (TrkB) [82]",
      "key": "5ca5219e6dc328dcf1fad13ed0edc7cb",
      "line": 181,
      "relation": "directlyIncreases",
      "source": 38,
      "target": 41
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "It has been shown that CREB is important in neurotrophin-mediated signaling linked to neuronal survival [79] and in neuroprotection via the PI3-kinase/Akt pathway [80].",
      "key": "4a4e2ff3ddb98913d631abde5ae920d9",
      "line": 166,
      "relation": "association",
      "source": 15,
      "target": 38
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "It has been shown that CREB is important in neurotrophin-mediated signaling linked to neuronal survival [79] and in neuroprotection via the PI3-kinase/Akt pathway [80].",
      "key": "5a11e0084b8dc712264fa1b92e332d6b",
      "line": 167,
      "relation": "association",
      "source": 15,
      "target": 19
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "It has been shown that CREB is important in neurotrophin-mediated signaling linked to neuronal survival [79] and in neuroprotection via the PI3-kinase/Akt pathway [80].",
      "key": "5b6fd5806a1ef11b1192f3395e0cca50",
      "line": 169,
      "relation": "association",
      "source": 9,
      "target": 38
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "It has been shown that CREB is important in neurotrophin-mediated signaling linked to neuronal survival [79] and in neuroprotection via the PI3-kinase/Akt pathway [80].",
      "key": "31903c183158251b2f2da8e1e153f6dd",
      "line": 170,
      "relation": "association",
      "source": 9,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Contributing to a feedforward mechanism, CREB is believed to upregulate neurotrophin expression and activity, importantly, brain derived neurotrophic factor (BDNF), which is important in modulating synaptic plasticity [81], and a neurotrophin target receptor, the tropomyosin receptor kinase receptor B (TrkB) [82]",
      "key": "9af07dd9c954cef3f8681f99dbc09949",
      "line": 180,
      "relation": "regulates",
      "source": 37,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "An example of an intriguing crossover to AD for an orally active free radical scavenger,edaravone, originally developed for acute ischemic stroke, was discovered wherein strong reductions in Aβ-induced oxidation, APP processing, Aβ deposition, neuroinflammation, neurite and dendritic loss, and synaptic and behavioral dysfunction were observed in in vitro and in vivo APP models [83].",
      "key": "e7d41f42c58a50883dc0c417f54987bc",
      "line": 186,
      "relation": "decreases",
      "source": 3,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "An example of an intriguing crossover to AD for an orally active free radical scavenger,edaravone, originally developed for acute ischemic stroke, was discovered wherein strong reductions in Aβ-induced oxidation, APP processing, Aβ deposition, neuroinflammation, neurite and dendritic loss, and synaptic and behavioral dysfunction were observed in in vitro and in vivo APP models [83].",
      "key": "552dac5bc13f56a39531ba4921d59778",
      "line": 187,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 3,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "An example of an intriguing crossover to AD for an orally active free radical scavenger,edaravone, originally developed for acute ischemic stroke, was discovered wherein strong reductions in Aβ-induced oxidation, APP processing, Aβ deposition, neuroinflammation, neurite and dendritic loss, and synaptic and behavioral dysfunction were observed in in vitro and in vivo APP models [83].",
      "key": "e8e2ae70403770cc633e4b6cd3429606",
      "line": 189,
      "relation": "decreases",
      "source": 3,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "An example of an intriguing crossover to AD for an orally active free radical scavenger,edaravone, originally developed for acute ischemic stroke, was discovered wherein strong reductions in Aβ-induced oxidation, APP processing, Aβ deposition, neuroinflammation, neurite and dendritic loss, and synaptic and behavioral dysfunction were observed in in vitro and in vivo APP models [83].",
      "key": "7045cf69f30935a4a096aee4d8774277",
      "line": 190,
      "relation": "decreases",
      "source": 3,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "An example of an intriguing crossover to AD for an orally active free radical scavenger,edaravone, originally developed for acute ischemic stroke, was discovered wherein strong reductions in Aβ-induced oxidation, APP processing, Aβ deposition, neuroinflammation, neurite and dendritic loss, and synaptic and behavioral dysfunction were observed in in vitro and in vivo APP models [83].",
      "key": "ef55602da40a467801cfee466472e500",
      "line": 191,
      "relation": "decreases",
      "source": 3,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "An example of an intriguing crossover to AD for an orally active free radical scavenger,edaravone, originally developed for acute ischemic stroke, was discovered wherein strong reductions in Aβ-induced oxidation, APP processing, Aβ deposition, neuroinflammation, neurite and dendritic loss, and synaptic and behavioral dysfunction were observed in in vitro and in vivo APP models [83].",
      "key": "3304cd49218937a617ac31b0e4116216",
      "line": 192,
      "relation": "decreases",
      "source": 3,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "An example of an intriguing crossover to AD for an orally active free radical scavenger,edaravone, originally developed for acute ischemic stroke, was discovered wherein strong reductions in Aβ-induced oxidation, APP processing, Aβ deposition, neuroinflammation, neurite and dendritic loss, and synaptic and behavioral dysfunction were observed in in vitro and in vivo APP models [83].",
      "key": "bc7855eefac6b761cc341713a43f3bef",
      "line": 193,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "decreases",
      "source": 3,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "An example of an intriguing crossover to AD for an orally active free radical scavenger,edaravone, originally developed for acute ischemic stroke, was discovered wherein strong reductions in Aβ-induced oxidation, APP processing, Aβ deposition, neuroinflammation, neurite and dendritic loss, and synaptic and behavioral dysfunction were observed in in vitro and in vivo APP models [83].",
      "key": "b12887279b192641b32cb624a84c357e",
      "line": 194,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "decreases",
      "source": 3,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "An example of an intriguing crossover to AD for an orally active free radical scavenger,edaravone, originally developed for acute ischemic stroke, was discovered wherein strong reductions in Aβ-induced oxidation, APP processing, Aβ deposition, neuroinflammation, neurite and dendritic loss, and synaptic and behavioral dysfunction were observed in in vitro and in vivo APP models [83].",
      "key": "a103eb40a251a95d51f8e5ca5c5faa25",
      "line": 195,
      "relation": "increases",
      "source": 3,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "An example of an intriguing crossover to AD for an orally active free radical scavenger,edaravone, originally developed for acute ischemic stroke, was discovered wherein strong reductions in Aβ-induced oxidation, APP processing, Aβ deposition, neuroinflammation, neurite and dendritic loss, and synaptic and behavioral dysfunction were observed in in vitro and in vivo APP models [83].",
      "key": "c8f9b7e1057804a0c13b1675007c40d9",
      "line": 196,
      "relation": "increases",
      "source": 3,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Collectively, the findings indicate the potential of the N terminal Aβ peptides as effective neuroprotective agents against Aβ-linked neuronal toxicity, synaptic inhibition, and behavioral deficits (Box 1).",
      "key": "80a80439306072bfc677840cc22774a9",
      "line": 236,
      "relation": "positiveCorrelation",
      "source": 18,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Aβ, primarily in monomeric form, appears to be neuroprotective [84]; but it would be difficult, if not impossible, to control the concentration and structural form of Aβ in vivo [85].",
      "key": "8bd4d85f61d2268f4f56d86e84657383",
      "line": 201,
      "relation": "increases",
      "source": 4,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Using mutational analysis together with physiological and behavioral assays in mouse models, it was determined the hydrophilic N terminal domain of Aβ is responsible for the neuromodulatory activity of full-length Aβ [86].",
      "key": "d478e90aecbe877b7f3bbe1d8faed3d5",
      "line": 207,
      "object": {
        "location": {
          "name": "Neurons",
          "namespace": "MESH"
        },
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 51,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Specifically, the N terminal Aβ fragment and the N-Aβ core rescued full length Aβ-induced mitochondrial dysfunction, oxidative stress, and apoptotic neuronal death in vitro in rodent neuron models, whether added as cotreatment or, notably, post-Aβ treatment [88].",
      "key": "ea210ad619816bba512c73443d9f6ffa",
      "line": 224,
      "relation": "decreases",
      "source": 51,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Specifically, the N terminal Aβ fragment and the N-Aβ core rescued full length Aβ-induced mitochondrial dysfunction, oxidative stress, and apoptotic neuronal death in vitro in rodent neuron models, whether added as cotreatment or, notably, post-Aβ treatment [88].",
      "key": "bc3aac271948b7a036b0bd7d4b3ee4c3",
      "line": 225,
      "relation": "decreases",
      "source": 51,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Specifically, the N terminal Aβ fragment and the N-Aβ core rescued full length Aβ-induced mitochondrial dysfunction, oxidative stress, and apoptotic neuronal death in vitro in rodent neuron models, whether added as cotreatment or, notably, post-Aβ treatment [88].",
      "key": "d7c08c79c7bb130c78028ea47a065f3a",
      "line": 228,
      "relation": "decreases",
      "source": 51,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Collectively, the findings indicate the potential of the N terminal Aβ peptides as effective neuroprotective agents against Aβ-linked neuronal toxicity, synaptic inhibition, and behavioral deficits (Box 1).",
      "key": "916b5ff66a4452d809d37a0df28913a3",
      "line": 235,
      "relation": "increases",
      "source": 51,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Collectively, the findings indicate the potential of the N terminal Aβ peptides as effective neuroprotective agents against Aβ-linked neuronal toxicity, synaptic inhibition, and behavioral deficits (Box 1).",
      "key": "5c507b3bcf0e1f0c169c49723d850f88",
      "line": 236,
      "relation": "positiveCorrelation",
      "source": 51,
      "target": 18
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Collectively, the findings indicate the potential of the N terminal Aβ peptides as effective neuroprotective agents against Aβ-linked neuronal toxicity, synaptic inhibition, and behavioral deficits (Box 1).",
      "key": "f24bd9579e14f79727d298686b1eee6b",
      "line": 238,
      "relation": "decreases",
      "source": 51,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Collectively, the findings indicate the potential of the N terminal Aβ peptides as effective neuroprotective agents against Aβ-linked neuronal toxicity, synaptic inhibition, and behavioral deficits (Box 1).",
      "key": "9716387ed301d5ce22c89da10307d495",
      "line": 240,
      "relation": "increases",
      "source": 51,
      "target": 17
    },
    {
      "key": "a3d555456bb1df0e486b8b78a48d6fcf",
      "relation": "hasVariant",
      "source": 48,
      "target": 51
    },
    {
      "key": "ebe0906294037fab36b15da6470fc6fe",
      "relation": "partOf",
      "source": 48,
      "target": 32
    },
    {
      "key": "9543429d82b023f44a1157b344b80eb4",
      "relation": "hasVariant",
      "source": 48,
      "target": 49
    },
    {
      "key": "77f804ce5f2b0a3d7ea4126d954bed4f",
      "relation": "hasVariant",
      "source": 48,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Specifically, the N terminal Aβ fragment and the N-Aβ core rescued full length Aβ-induced mitochondrial dysfunction, oxidative stress, and apoptotic neuronal death in vitro in rodent neuron models, whether added as cotreatment or, notably, post-Aβ treatment [88].",
      "key": "16040cd3a38fbc1c080889228efc80ef",
      "line": 226,
      "relation": "increases",
      "source": 48,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Specifically, the N terminal Aβ fragment and the N-Aβ core rescued full length Aβ-induced mitochondrial dysfunction, oxidative stress, and apoptotic neuronal death in vitro in rodent neuron models, whether added as cotreatment or, notably, post-Aβ treatment [88].",
      "key": "5f4456f3c59bcc00257427ef7f86a8cf",
      "line": 227,
      "relation": "increases",
      "source": 48,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Specifically, the N terminal Aβ fragment and the N-Aβ core rescued full length Aβ-induced mitochondrial dysfunction, oxidative stress, and apoptotic neuronal death in vitro in rodent neuron models, whether added as cotreatment or, notably, post-Aβ treatment [88].",
      "key": "30a0f7974bb47951e4f48181ecb4f6eb",
      "line": 229,
      "relation": "decreases",
      "source": 48,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Consequently, a nontoxic fragment of Aβ (1–15/16) that is derived from the N terminal domain, naturally derived from Aβ by the action of α-secretase, and does not oligomerize [87], was shown to be more effective in regard to neuromodulatory activity compared with that observed for Aβ [86].",
      "key": "3033ac5c5daa915e7f2ddd3522282824",
      "line": 213,
      "relation": "increases",
      "source": 32,
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Consequently, a nontoxic fragment of Aβ (1–15/16) that is derived from the N terminal domain, naturally derived from Aβ by the action of α-secretase, and does not oligomerize [87], was shown to be more effective in regard to neuromodulatory activity compared with that observed for Aβ [86].",
      "key": "7141c8eb9a3905e96a4af437958cbb80",
      "line": 214,
      "relation": "increases",
      "source": 32,
      "target": 50
    },
    {
      "key": "20173c9cd39c3aa0b0c8935fc249a977",
      "relation": "partOf",
      "source": 47,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Consequently, a nontoxic fragment of Aβ (1–15/16) that is derived from the N terminal domain, naturally derived from Aβ by the action of α-secretase, and does not oligomerize [87], was shown to be more effective in regard to neuromodulatory activity compared with that observed for Aβ [86].",
      "key": "aaaf5c3f379e18e26c6af607ce372e13",
      "line": 215,
      "relation": "decreases",
      "source": 49,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Consequently, a nontoxic fragment of Aβ (1–15/16) that is derived from the N terminal domain, naturally derived from Aβ by the action of α-secretase, and does not oligomerize [87], was shown to be more effective in regard to neuromodulatory activity compared with that observed for Aβ [86].",
      "key": "9f88a711990420e2502cb0ce12c9d2fa",
      "line": 217,
      "object": {
        "location": {
          "name": "Neurons",
          "namespace": "MESH"
        },
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 49,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Consequently, a nontoxic fragment of Aβ (1–15/16) that is derived from the N terminal domain, naturally derived from Aβ by the action of α-secretase, and does not oligomerize [87], was shown to be more effective in regard to neuromodulatory activity compared with that observed for Aβ [86].",
      "key": "27f66af387ece36f3eb3d5d72c53d2e0",
      "line": 216,
      "relation": "decreases",
      "source": 50,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Forest KH",
          "Nichols RA"
        ],
        "date": "2019-08-01",
        "db": "PubMed",
        "db_id": "31248781",
        "db_name": "Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.",
        "first": "Forest KH",
        "journal": "Trends in molecular medicine",
        "last": "Nichols RA",
        "pages": "685-695",
        "volume": "25"
      },
      "evidence": "Consequently, a nontoxic fragment of Aβ (1–15/16) that is derived from the N terminal domain, naturally derived from Aβ by the action of α-secretase, and does not oligomerize [87], was shown to be more effective in regard to neuromodulatory activity compared with that observed for Aβ [86].",
      "key": "49f0b8c19380cacf806b6bc4a62eb5bf",
      "line": 218,
      "object": {
        "location": {
          "name": "Neurons",
          "namespace": "MESH"
        },
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 50,
      "target": 48
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"amyloid-beta\")",
      "concept": {
        "name": "amyloid-beta",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "e9557ea6ec74113b73fe23f4bd76b524"
    },
    {
      "bel": "a(CHEBI:glucose)",
      "concept": {
        "name": "glucose",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "8b4d8974cf8c0e5830f78bb44168cf4d"
    },
    {
      "bel": "a(CONSO:\"amyloid-beta oligomers\")",
      "concept": {
        "name": "amyloid-beta oligomers",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "34014daa17e0fc6d25c4a657cd071f3a"
    },
    {
      "bel": "a(DRUGBANK:Edaravone)",
      "concept": {
        "name": "Edaravone",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "82a11bfa927d0e1b7043d57415663455"
    },
    {
      "bel": "a(MESH:\"Amyloid beta-Peptides\")",
      "concept": {
        "name": "Amyloid beta-Peptides",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "1db1ada7870d4670fee87d49811c18f1"
    },
    {
      "bel": "a(MESH:\"Autonomic Nervous System\")",
      "concept": {
        "name": "Autonomic Nervous System",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "295543cef9942212ac29f5df99ce9df2"
    },
    {
      "bel": "a(MESH:Dendrites)",
      "concept": {
        "name": "Dendrites",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "4358e98b2ef03546daccffc5f9017aa5"
    },
    {
      "bel": "a(MESH:Neurites)",
      "concept": {
        "name": "Neurites",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "192f89a6158de53e2d132cdabb1553da"
    },
    {
      "bel": "a(MESH:Neurons)",
      "concept": {
        "name": "Neurons",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "c429b8780142c504cf23cacfc2fa2b09"
    },
    {
      "bel": "bp(CONSO:\"PI3K-Akt signaling pathway\")",
      "concept": {
        "name": "PI3K-Akt signaling pathway",
        "namespace": "CONSO"
      },
      "function": "BiologicalProcess",
      "id": "288496518c9a4d85d363ac156833d945"
    },
    {
      "bel": "bp(GO:\"learning or memory\")",
      "concept": {
        "name": "learning or memory",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "f7990d886000f2ae69441a960a7d6236"
    },
    {
      "bel": "bp(GO:\"negative regulation of type B pancreatic cell development\")",
      "concept": {
        "name": "negative regulation of type B pancreatic cell development",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "e9a83c83fef463c73edeb8f3ef059210"
    },
    {
      "bel": "bp(GO:\"neuron apoptotic process\")",
      "concept": {
        "name": "neuron apoptotic process",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "d73c31b799210c2ae76d3426d593149c"
    },
    {
      "bel": "bp(GO:\"neuron death\")",
      "concept": {
        "name": "neuron death",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "5af039c1f3120f7215931236c3c03804"
    },
    {
      "bel": "bp(GO:\"neuronal signal transduction\")",
      "concept": {
        "name": "neuronal signal transduction",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "2f4dbcfb8c513ef96e410be6f1f5b973"
    },
    {
      "bel": "bp(GO:\"neurotrophin signaling pathway\")",
      "concept": {
        "name": "neurotrophin signaling pathway",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "7aa548f05a3c89653d38f20b3ce3f686"
    },
    {
      "bel": "bp(GO:\"stress-activated protein kinase signaling cascade\")",
      "concept": {
        "name": "stress-activated protein kinase signaling cascade",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "906009290fc868ab497e8e415e1e1ed2"
    },
    {
      "bel": "bp(GO:\"synaptic signaling\")",
      "concept": {
        "name": "synaptic signaling",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "47e244f71f5d21a426ba920c40e7b9ed"
    },
    {
      "bel": "bp(GO:behavior)",
      "concept": {
        "name": "behavior",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "77f1822074b59deb82cc4661eb6d5aa5"
    },
    {
      "bel": "bp(MESH:\"Cell Survival\")",
      "concept": {
        "name": "Cell Survival",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "c6f26bea83787c63169a3fcb728da799"
    },
    {
      "bel": "bp(MESH:\"Neuronal Plasticity\")",
      "concept": {
        "name": "Neuronal Plasticity",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "7e5d48cf7a27a09a15d969d961c71347"
    },
    {
      "bel": "bp(MESH:Neuroprotection)",
      "concept": {
        "name": "Neuroprotection",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "94345c5831649e39b0f93286f5357249"
    },
    {
      "bel": "complex(CONSO:\"gamma-secretase\")",
      "concept": {
        "name": "gamma-secretase",
        "namespace": "CONSO"
      },
      "function": "Complex",
      "id": "6965f86526ecbfcb891a17a945998295"
    },
    {
      "bel": "complex(GO:\"neurotransmitter receptor complex\")",
      "concept": {
        "name": "neurotransmitter receptor complex",
        "namespace": "GO"
      },
      "function": "Complex",
      "id": "6de7fdfca63cdf74fab7a6f0d7b9823d"
    },
    {
      "bel": "complex(p(CHEBI:\"amyloid-beta\"), p(MESH:\"Receptors, Islet Amyloid Polypeptide\"))",
      "function": "Complex",
      "id": "bf6d821e493f4012b3433f67116ea766",
      "members": [
        {
          "bel": "p(CHEBI:\"amyloid-beta\")",
          "concept": {
            "name": "amyloid-beta",
            "namespace": "CHEBI"
          },
          "function": "Protein",
          "id": "60c358201f83abc62143668c68d1a3fa"
        },
        {
          "bel": "p(MESH:\"Receptors, Islet Amyloid Polypeptide\")",
          "concept": {
            "name": "Receptors, Islet Amyloid Polypeptide",
            "namespace": "MESH"
          },
          "function": "Protein",
          "id": "f46fb391fcc6c977731b87f9382ff434"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:IAPP), p(MESH:\"Receptors, Islet Amyloid Polypeptide\"))",
      "function": "Complex",
      "id": "80c0d6ba8859ad15069582045f810c55",
      "members": [
        {
          "bel": "p(HGNC:IAPP)",
          "concept": {
            "name": "IAPP",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "772b24fa8b87e261d3d5735d276f511f"
        },
        {
          "bel": "p(MESH:\"Receptors, Islet Amyloid Polypeptide\")",
          "concept": {
            "name": "Receptors, Islet Amyloid Polypeptide",
            "namespace": "MESH"
          },
          "function": "Protein",
          "id": "f46fb391fcc6c977731b87f9382ff434"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:\"amyloid-beta\"), p(HGNC:GRM5), p(HGNC:PRNP))",
      "function": "Composite",
      "id": "9784374a4044e0a0c6d8533617c7955a",
      "members": [
        {
          "bel": "a(CHEBI:\"amyloid-beta\")",
          "concept": {
            "name": "amyloid-beta",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "e9557ea6ec74113b73fe23f4bd76b524"
        },
        {
          "bel": "p(HGNC:GRM5)",
          "concept": {
            "name": "GRM5",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "19f093133fdf1bb1564cbcbe351d9156"
        },
        {
          "bel": "p(HGNC:PRNP)",
          "concept": {
            "name": "PRNP",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "0df8caec1eedc2d8cf6b578ada69c73f"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:\"amyloid-beta\"), p(HGNCGENEFAMILY:\"Cholinergic receptors nicotinic subunits\"))",
      "function": "Composite",
      "id": "14e17f547760a960beba08716821053d",
      "members": [
        {
          "bel": "a(CHEBI:\"amyloid-beta\")",
          "concept": {
            "name": "amyloid-beta",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "e9557ea6ec74113b73fe23f4bd76b524"
        },
        {
          "bel": "p(HGNCGENEFAMILY:\"Cholinergic receptors nicotinic subunits\")",
          "concept": {
            "name": "Cholinergic receptors nicotinic subunits",
            "namespace": "HGNCGENEFAMILY"
          },
          "function": "Protein",
          "id": "8038209bc0b5bd919a7208d644f913f8"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:\"amyloid-beta\"), p(HGNCGENEFAMILY:\"Glutamate ionotropic receptor AMPA type subunits\"))",
      "function": "Composite",
      "id": "eab83b8192ee33cc36d6ecc7ecdac174",
      "members": [
        {
          "bel": "a(CHEBI:\"amyloid-beta\")",
          "concept": {
            "name": "amyloid-beta",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "e9557ea6ec74113b73fe23f4bd76b524"
        },
        {
          "bel": "p(HGNCGENEFAMILY:\"Glutamate ionotropic receptor AMPA type subunits\")",
          "concept": {
            "name": "Glutamate ionotropic receptor AMPA type subunits",
            "namespace": "HGNCGENEFAMILY"
          },
          "function": "Protein",
          "id": "2b014fdb0e42ce7d4f844ac1d4fe4f83"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:\"amyloid-beta\"), p(HGNCGENEFAMILY:\"Glutamate ionotropic receptor NMDA type subunits\"))",
      "function": "Composite",
      "id": "cd49fde5168e7b37289fceb128b925c1",
      "members": [
        {
          "bel": "a(CHEBI:\"amyloid-beta\")",
          "concept": {
            "name": "amyloid-beta",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "e9557ea6ec74113b73fe23f4bd76b524"
        },
        {
          "bel": "p(HGNCGENEFAMILY:\"Glutamate ionotropic receptor NMDA type subunits\")",
          "concept": {
            "name": "Glutamate ionotropic receptor NMDA type subunits",
            "namespace": "HGNCGENEFAMILY"
          },
          "function": "Protein",
          "id": "b7afccdb6102ed56132b102ce2e5f6e6"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:\"amyloid-beta\"), p(MESH:\"Receptors, Islet Amyloid Polypeptide\"))",
      "function": "Composite",
      "id": "45a92ccc249f0ad6f21c3c72752e638f",
      "members": [
        {
          "bel": "a(CHEBI:\"amyloid-beta\")",
          "concept": {
            "name": "amyloid-beta",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "e9557ea6ec74113b73fe23f4bd76b524"
        },
        {
          "bel": "p(MESH:\"Receptors, Islet Amyloid Polypeptide\")",
          "concept": {
            "name": "Receptors, Islet Amyloid Polypeptide",
            "namespace": "MESH"
          },
          "function": "Protein",
          "id": "f46fb391fcc6c977731b87f9382ff434"
        }
      ]
    },
    {
      "bel": "composite(complex(CONSO:\"gamma-secretase\"), p(HGNC:APP), p(HGNC:BACE1))",
      "function": "Composite",
      "id": "07cd186ca9b316c610259df26dd4585f",
      "members": [
        {
          "bel": "complex(CONSO:\"gamma-secretase\")",
          "concept": {
            "name": "gamma-secretase",
            "namespace": "CONSO"
          },
          "function": "Complex",
          "id": "6965f86526ecbfcb891a17a945998295"
        },
        {
          "bel": "p(HGNC:APP)",
          "concept": {
            "name": "APP",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "d43ae551265c6b6a27038d0b036848cf"
        },
        {
          "bel": "p(HGNC:BACE1)",
          "concept": {
            "name": "BACE1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "334dd03e9a5f223f13995e497b1c156e"
        }
      ]
    },
    {
      "bel": "composite(p(MESH:\"Amyloid Precursor Protein Secretases\"), p(MESH:\"Amyloid beta-Peptides\"))",
      "function": "Composite",
      "id": "9ae95292a6e0a42a24244eb7c8dc0003",
      "members": [
        {
          "bel": "p(MESH:\"Amyloid Precursor Protein Secretases\")",
          "concept": {
            "name": "Amyloid Precursor Protein Secretases",
            "namespace": "MESH"
          },
          "function": "Protein",
          "id": "9fd73a5cf2d0a2bc2ef5d992e16c496e"
        },
        {
          "bel": "p(MESH:\"Amyloid beta-Peptides\")",
          "concept": {
            "name": "Amyloid beta-Peptides",
            "namespace": "MESH"
          },
          "function": "Protein",
          "id": "3928201d140842a4fc21ce71a9d4010b"
        }
      ]
    },
    {
      "bel": "p(CHEBI:\"amyloid-beta\")",
      "concept": {
        "name": "amyloid-beta",
        "namespace": "CHEBI"
      },
      "function": "Protein",
      "id": "60c358201f83abc62143668c68d1a3fa"
    },
    {
      "bel": "p(HGNC:APP)",
      "concept": {
        "name": "APP",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "d43ae551265c6b6a27038d0b036848cf"
    },
    {
      "bel": "p(HGNC:APP, frag(\"?\"))",
      "concept": {
        "name": "APP",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1d7a8a2d778541f6083221fa6bb73dec",
      "variants": [
        {
          "kind": "frag",
          "missing": "?"
        }
      ]
    },
    {
      "bel": "p(HGNC:BACE1)",
      "concept": {
        "name": "BACE1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "334dd03e9a5f223f13995e497b1c156e"
    },
    {
      "bel": "p(HGNC:BDNF)",
      "concept": {
        "name": "BDNF",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a638d5f84b9678f17c8795852300134a"
    },
    {
      "bel": "p(HGNC:CREBBP)",
      "concept": {
        "name": "CREBBP",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "46148e81658994544d74b5db695e5cd8"
    },
    {
      "bel": "p(HGNC:GRM5)",
      "concept": {
        "name": "GRM5",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "19f093133fdf1bb1564cbcbe351d9156"
    },
    {
      "bel": "p(HGNC:IAPP)",
      "concept": {
        "name": "IAPP",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "772b24fa8b87e261d3d5735d276f511f"
    },
    {
      "bel": "p(HGNC:NTRK2)",
      "concept": {
        "name": "NTRK2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5873dc57711d54aff73ef2aa04a42017"
    },
    {
      "bel": "p(HGNC:PRNP)",
      "concept": {
        "name": "PRNP",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0df8caec1eedc2d8cf6b578ada69c73f"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Cholinergic receptors nicotinic subunits\")",
      "concept": {
        "name": "Cholinergic receptors nicotinic subunits",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "8038209bc0b5bd919a7208d644f913f8"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Glutamate ionotropic receptor AMPA type subunits\")",
      "concept": {
        "name": "Glutamate ionotropic receptor AMPA type subunits",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "2b014fdb0e42ce7d4f844ac1d4fe4f83"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Glutamate ionotropic receptor NMDA type subunits\")",
      "concept": {
        "name": "Glutamate ionotropic receptor NMDA type subunits",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "b7afccdb6102ed56132b102ce2e5f6e6"
    },
    {
      "bel": "p(HGNCGENEFAMILY:Neurotrophins)",
      "concept": {
        "name": "Neurotrophins",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "e26616e373fcca197a60899b2c4e0af2"
    },
    {
      "bel": "p(MESH:\"Amyloid Precursor Protein Secretases\")",
      "concept": {
        "name": "Amyloid Precursor Protein Secretases",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "9fd73a5cf2d0a2bc2ef5d992e16c496e"
    },
    {
      "bel": "p(MESH:\"Amyloid beta-Peptides\")",
      "concept": {
        "name": "Amyloid beta-Peptides",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "3928201d140842a4fc21ce71a9d4010b"
    },
    {
      "bel": "p(MESH:\"Amyloid beta-Peptides\", frag(\"1_15\"))",
      "concept": {
        "name": "Amyloid beta-Peptides",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "55d87984237438201c0b7817539cb36b",
      "variants": [
        {
          "kind": "frag",
          "start": 1,
          "stop": 15
        }
      ]
    },
    {
      "bel": "p(MESH:\"Amyloid beta-Peptides\", frag(\"1_16\"))",
      "concept": {
        "name": "Amyloid beta-Peptides",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "61d83aaebcc8ad74f6bdb6ba924ec2f7",
      "variants": [
        {
          "kind": "frag",
          "start": 1,
          "stop": 16
        }
      ]
    },
    {
      "bel": "p(MESH:\"Amyloid beta-Peptides\", frag(\"1_?\"))",
      "concept": {
        "name": "Amyloid beta-Peptides",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "e61c2f101d637e44ab6e5b29e518b5e9",
      "variants": [
        {
          "kind": "frag",
          "start": 1,
          "stop": "?"
        }
      ]
    },
    {
      "bel": "p(MESH:\"Neurofibrillary Tangles\")",
      "concept": {
        "name": "Neurofibrillary Tangles",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "23b57fa4c2111fd8150d349cd2c5c2d0"
    },
    {
      "bel": "p(MESH:\"Receptors, Islet Amyloid Polypeptide\")",
      "concept": {
        "name": "Receptors, Islet Amyloid Polypeptide",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "f46fb391fcc6c977731b87f9382ff434"
    },
    {
      "bel": "p(MESH:Caspases)",
      "concept": {
        "name": "Caspases",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "4b8cd4adfc83420a440aec92462dc0b7"
    },
    {
      "bel": "path(CONSO:\"APP processing\")",
      "concept": {
        "name": "APP processing",
        "namespace": "CONSO"
      },
      "function": "Pathology",
      "id": "e79eeb1b46bdb3a8058450313f7064d3"
    },
    {
      "bel": "path(CONSO:\"mitochondrial dysfunction\")",
      "concept": {
        "name": "mitochondrial dysfunction",
        "namespace": "CONSO"
      },
      "function": "Pathology",
      "id": "14a330b2e354b7af4f380b05664a5728"
    },
    {
      "bel": "path(CONSO:Neurodegeneration)",
      "concept": {
        "name": "Neurodegeneration",
        "namespace": "CONSO"
      },
      "function": "Pathology",
      "id": "e18248b0d7323caa29b448e45437a1e5"
    },
    {
      "bel": "path(CONSO:neuroinflammation)",
      "concept": {
        "name": "neuroinflammation",
        "namespace": "CONSO"
      },
      "function": "Pathology",
      "id": "b264621022ed4df78748c6c4e198145d"
    },
    {
      "bel": "path(DOID:\"Alzheimer's disease\")",
      "concept": {
        "name": "Alzheimer's disease",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "bab8638a4ae2b144ee036438e0a858da"
    },
    {
      "bel": "path(DOID:\"diabetes mellitus\")",
      "concept": {
        "name": "diabetes mellitus",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "938cd6abfb7292beb1567c134a06833b"
    },
    {
      "bel": "path(DOID:\"mental depression\")",
      "concept": {
        "name": "mental depression",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "444223db67421fa96923920d0a8fd533"
    },
    {
      "bel": "path(DOID:\"sleep disorder\")",
      "concept": {
        "name": "sleep disorder",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "16b2af38a96cf5c3aed64dfd51512de6"
    },
    {
      "bel": "path(HP:\"Ischemic stroke\")",
      "concept": {
        "name": "Ischemic stroke",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "50cfd5a1cf06b79013af39a75b8ceca5"
    },
    {
      "bel": "path(HP:Agitation)",
      "concept": {
        "name": "Agitation",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "db336c699f840cf5228a8a4a7eb05346"
    },
    {
      "bel": "path(MESH:\"Anxiety Disorders\")",
      "concept": {
        "name": "Anxiety Disorders",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "ec49ebadb24f24cc0c46b810c82f0f78"
    },
    {
      "bel": "path(MESH:\"Cell Death\")",
      "concept": {
        "name": "Cell Death",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "e272f89e4ce648a10de7de994d3e1f31"
    },
    {
      "bel": "path(MESH:\"Executive Function\")",
      "concept": {
        "name": "Executive Function",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "cf426453e61e2674d5e1e153c4463cd3"
    },
    {
      "bel": "path(MESH:\"Language Disorders\")",
      "concept": {
        "name": "Language Disorders",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "619153f2baea94f9174cc1c4763b5d7a"
    },
    {
      "bel": "path(MESH:\"Oxidative Stress\")",
      "concept": {
        "name": "Oxidative Stress",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "5d5071d9dea362c9b9b6ee5de9eb67be"
    },
    {
      "bel": "path(MESH:\"Plaque, Amyloid\")",
      "concept": {
        "name": "Plaque, Amyloid",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "ff45c3caeb411cd232d96d6ed01854d5"
    },
    {
      "bel": "path(MESH:Attention)",
      "concept": {
        "name": "Attention",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "f22e7196f5d0614ad79325e3690466ec"
    },
    {
      "bel": "path(MESH:Judgment)",
      "concept": {
        "name": "Judgment",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "e03e69b05f06c798b9bdbdf3c8415913"
    },
    {
      "bel": "path(MESH:Orientation)",
      "concept": {
        "name": "Orientation",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "73435bce21936d7f088fb9f9a5684fce"
    }
  ]
}